The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib
Mai Nagasaka(Nagoya City University), Luc Friboulet(Inserm)
Cited by 0
Related Papers
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
|Cancer Discovery|2014|842
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
|Annals of Oncology|2022|138
Resistance to Selective FGFR Inhibitors in <i>FGFR-</i> Driven Urothelial Cancer
|Cancer Discovery|2023|69